LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 21, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that pre-clinical tests conducted by scientists at MultiCell's San Diego laboratories showed that MultiCell Immunotherapeutics, Inc.'s (MCTI's) toll receptor technology was able to reduce pulmonary virus titers by 1,000- fold in the H1N1 strain of flu to barely detectable levels. These results indicate that the technology may be able to reduce viral load in avian influenza. The H5N1 avian flu contains many of the same proteins as the H1N1 strain of flu, so the HINI results are projected to be important to the understanding of developing an immunotherapeutic against avian flu.
